Floatz logo

Dendritic Cell Tumor Fusion

Immunologic Factors

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Immunologic Factors cohort.

Asset / SponsorPhaseRating
Ceftriaxone
Tianjin Medical University General Hospital
Phase 2CCC
PROPRANOLOL
Tianjin Medical University General Hospital
Phase 2CCC
Interleukin-12
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2CCC
Cynk-001
Celularity Incorporated
Phase 1D

Same molecule, other indications

Dendritic Cell Tumor Fusion is also rated in:

Primary Peritoneal CancerDormant
CCC
Indicative ·
51 / 100
View asset →
Fallopian Tube CancerDormant
CCC
Indicative ·
48 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →